Global Cardiovascular Clinical Trials Market Overview 2024: Size, Growth Rate, and Segments
The cardiovascular clinical trials
global market report 2024 from The Business Research Company provides
comprehensive market statistics, including global market size, regional shares,
competitor market share, detailed segments, trends, and opportunities. This
report offers an in-depth analysis of current and future industry scenarios,
delivering a complete perspective for thriving in the industrial automation
software market.
Cardiovascular Clinical Trials Market, 2024 report by The Business Research
Company offers comprehensive insights into the current state of the market and
highlights future growth opportunities.
Market Size -
The cardiovascular clinical trials market size has grown strongly in recent
years. It will grow from $4.99 billion in 2023 to $5.34 billion in 2024 at a
compound annual growth rate (CAGR) of 7.0%.
The growth in the historic period can be attributed to increased
myocardial infarction, regulatory environment, increased disease burden, advancements
in genomics, and increased demand for new drug development.
The cardiovascular clinical trials market size is expected to see strong growth
in the next few years. It will grow to $7.03 billion in 2028 at a compound
annual growth rate (CAGR) of 7.1%. The
growth in the forecast period can be attributed to an aging population,
emerging markets, precision medicine, digital health technologies, and a focus
on patient-centric trials. Major trends in the forecast period include
increased collaborations, technological advancements, product innovations, new
product developments, and the launch of generic versions of combination drugs.
Order your report now for swift delivery
@
https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report
Scope Of Cardiovascular Clinical Trials
Market
The Business Research Company's reports encompass a wide range of information,
including:
1. Market Size (Historic and Forecast): Analysis of the market's historical
performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market
landscape.
4. Key Segments: Breakdown of the market into its primary segments and their
respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and
geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting
the market.
Cardiovascular Clinical Trials Market Overview
Market Drivers -
The growing incidence of cardiovascular diseases is expected to drive the
growth of the cardiovascular clinical trials market going forward.
Cardiovascular disease refers to a group of conditions affecting the heart and
blood vessels, including coronary artery disease, heart failure, and stroke.
There is an increased incidence of cardiovascular diseases due to various
factors, such as sedentary lifestyles, unhealthy diets, smoking, obesity, high
blood pressure, diabetes, and genetic predispositions. Cardiovascular clinical
trials help in discovering and validating new drugs that can more effectively
manage risk factors such as hypertension, high cholesterol, and diabetes, which
are significant contributors to CVDs. For instance, in May 2023, according to
the Centers for Disease Control And Prevention, a US-based governmental
organization, the percentage of coronary heart disease in adults aged 18 and
over in 2020 was 4.6%, which increased to 4.9% in 2021. Therefore, the growing
incidence of cardiovascular diseases is driving the growth of the
cardiovascular clinical trials market.
Market Trends -
Major companies operating in the cardiovascular clinical trials market are
focused on adopting strategic partnerships, such as contract research organization
(CRO) partnerships, to expand their distribution networks and reach a wider
customer base. A CRO partnership plays a crucial role in the clinical research
industry and involves collaborations between different types of companies to
provide specialized services and support for various aspects of clinical trials
and research. For instance, in September 2023, Cereno Scientific AB, a
Sweden-based biopharmaceutical company, collaborated with Clinical Trial
Consultants (CTC), a Sweden-based full-service CRO with a focus on clinical
conduct, to conduct a Phase I study for CS014, a histone deacetylase inhibitor
aimed at preventing arterial and venous thrombosis. CTC will also assist with
Phase I preparation processes such as study protocol development and the
clinical trial application process for the study, which will be conducted in
Sweden. This first-in-human Phase I trial is scheduled to begin in the first
half of 2024. This collaboration signifies a significant step in advancing
research on cardiovascular health.
The cardiovascular clinical trials
market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Indication : Acute Coronary Syndrome, Coronary Artery Disease, Ischemic
Heart Disease, Pulmonary Arterial Hypertension, Stroke, Cardiac Arrhythmias,
Heart Failure, Other Indications
Get an inside scoop of the
cardiovascular clinical trials market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15532&type=smp
Regional Insights -
North America was the largest region
in the cardiovascular clinical trials market in 2023. Asia-Pacific is expected to be the fastest-growing region in the
forecast period. The regions covered in the cardiovascular clinical trials
market report are Asia-Pacific, Western Europe, Eastern Europe, North America,
South America, Middle East, Africa.
Key Companies -
Major companies operating in the cardiovascular clinical trials market
are Pfizer Inc., Johnson & Johnson,
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., AstraZeneca PLC,
Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc.,
Boehringer Ingelheim International GmbH, Merck & Co. Inc., Baxter International
Inc., IQVIA Holdings Inc., SGS S.A., PPD Inc., WuXi AppTec Co. Ltd., Caidya,
Syneos Health Inc., Charles River Laboratories International Inc., Sanofi, ICON
plc, Medpace Holdings Inc., Cardiovascular Clinical Sciences., ProRelix
Services LLP, Worldwide Clinical Trials
Table of Contents
1. Executive Summary
2. Cardiovascular Clinical Trials Market Report Structure
3. Cardiovascular Clinical Trials Market Trends And Strategies
4. Cardiovascular Clinical Trials Market – Macro Economic Scenario
5. Cardiovascular Clinical Trials Market Size And Growth
…..
27. Cardiovascular Clinical Trials Market Competitor Landscape And Company
Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Comments
Post a Comment